Startup Monitors Patients On Life Support Without Invasive Steps

An Israeli startup that develops life support technology has announced advancements in its blood sensor that continuously monitors changes in a patient’s medical condition without having to draw blood.  

Inspira Technologies’ HYLA Blood Sensor is attached to the outer walls of artificial life support tubes and monitors the oxygen and carbon dioxide pressures of the blood flowing through it.

The company says that these parameters are known to be precise indicators of health disorders and patient deterioration. 

Now, Inspira has announced that the HYLA has achieved 95 percent accuracy compared to standard blood gas analyzers, which can only monitor the patient’s condition through intermittent and invasive blood tests. 

The results mark a significant step towards the device receiving US Food and Drug Administration (FDA) approval. Inspira expects its HYLA to be approved in the coming months. 

The HYLA was initially designed for the INSPIRA ART device, which inserts a cannula into the jugular vein, pulling blood with low oxygen levels into an “artificial lung.”

The device pumps oxygen into the blood and removes CO2 before sending it back into the body, reaching 95 percent oxygen saturation in about a minute.

Inspira says that plans are underway to create a variant of the HYLA as a standalone device.

“With our sensor technology, we are not only enriching our INSPIRA ART device line but also forging a path into the disposables market, setting the stage for groundbreaking developments in healthcare,” said Dagi Ben-Noon, CEO of Inspira.